Study of ZG005 in Patients With Advanced Solid Tumors

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

June 30, 2027

Conditions

Advanced Solid Tumor

Interventions

BIOLOGICAL

ZG005 for Injection

Recommended Phase 2 Dose (RP2D) of ZG005(20 mg/kg), intravenous infusion, once every 3 weeks.

Trial Locations (1)

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY